We didn't start as a
technology company.
We started it because agriculture failed us. In 2013–14, a single climate event wiped out an entire 5,000-acre ginger crop. Not because the demand wasn't there. Not because the farmers didn't work hard enough.
But because agriculture, as it exists today, is fundamentally unpredictable.
"What if agriculture didn't behave like agriculture? What if it behaved like manufacturing?"
Today, the world depends on medicinal plants for pharmaceuticals, nutraceuticals, and wellness products. Yet the industry is built on a fragile foundation — inconsistent quality, volatile supply, and zero control over the variables that actually determine value.
For a pharmaceutical company, this is not an inconvenience. It is a risk. A batch fails, and an entire product line is compromised.
Over four years and ₹146Cr of deep investment, we built a precision-controlled cultivation system — not for food, but for pharmaceutical-grade crops. Crops where value is not measured in kilograms, but in the consistency of bioactive compounds.
That question became Panama HydroX.